Traders Sell Teva Pharmaceutical Industries (TEVA) on Strength (TEVA)
Investors sold shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) on strength during trading on Tuesday. $61.04 million flowed into the stock on the tick-up and $80.00 million flowed out of the stock on the tick-down, for a money net flow of $18.96 million out of the stock. Of all companies tracked, Teva Pharmaceutical Industries had the 0th highest net out-flow for the day. Teva Pharmaceutical Industries traded up $0.17 for the day and closed at $18.92
Several equities analysts have issued reports on the company. Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 13th. BidaskClub upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. UBS Group reiterated a “neutral” rating and issued a $19.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Maxim Group reiterated a “hold” rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $24.00 target price on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 4th. Five analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $20.68.
The firm has a market capitalization of $19,530.00, a PE ratio of -3.25 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.
Institutional investors and hedge funds have recently modified their holdings of the stock. Fieldpoint Private Securities LLC purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $171,000. Arthur Zaske & Associates LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $372,000. Sterling Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $263,000. Point72 Asset Management L.P. acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $2,200,000. Finally, Chevy Chase Trust Holdings Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 81.5% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock valued at $215,000 after purchasing an additional 5,497 shares during the last quarter. Hedge funds and other institutional investors own 51.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theolympiareport.com/2017/12/28/traders-sell-teva-pharmaceutical-industries-teva-on-strength-teva-2.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.